Supported by independent educational grants from sanofi-aventis, Bristol-Myers Squibb and Medtronic
Low-density lipoprotein cholesterol/apolipoprotein B ratio may be a useful index that differs in statin-treated patients with and without coronary artery disease: a case control study.
Tani S, Saito Y, Anazawa T, et al. Int Heart J. 2011;52:343-347.
Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study.
Enseleit F, Sudano I, Périat D, et al. Eur Heart J. 2012. [Epub ahead of print
Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M, Yin L, Ingelsson E. Eur Heart J. 2011. [Epub ahead of print]
Effect of adding systematic family history enquiry to cardiovascular disease risk assessment in primary care: a matched-pair, cluster randomized trial.
Qureshi N, Armstrong S, Dhiman P, et al. Ann Intern Med. 2012;156:253-262.
Urinary bisphenol a concentration and risk of future coronary artery disease in apparently healthy men and women.
Melzer D, Osborne NJ, Henley WE, et al. Circulation. 2012;125:1482-1490.
Yaemsiri S, Sen S, Tinker L, et al. Ann Neurol. 2012. [Epub ahead of print]
Trends in Cardiovascular Health Metrics and Associations With All-Cause and CVD Mortality Among US Adults.
Yang Q, Cogswell ME, Flanders WD, et al. JAMA. 2012. [Epub ahead of print]
Boden WE. Circulation. 2012. [Epub ahead of print]
Comparative Outcomes for Patients Who Do and Do Not Undergo Percutaneous Coronary Intervention for Stable Coronary Artery Disease in New York.
Hannan EL, Samadashvili Z, Cozzens K, et al. Circulation. 2012. [Epub ahead of print]
Parker JD, Parker JO. Can J Cardiol. 2012; 28(Suppl A):S70-80.